Source: http://seekingalpha.com
Bridgewater Associates is one of the most well-known asset management
companies in the U.S. The famous hedge fund was founded by Ray Dalio in
1975. In 2010 and 2011, it was ranked as the largest and best-performing
hedge fund manager in the world. Like Soros, it employs a global macro
style of investment. The company currently has 1,200 employees. In 2011,
it was reported to have $122 billion worth of assets under its
management.
The top dividend stocks favored by Ray Dalio and
Bridgewater are shown in this article. My selection criteria for
screening is based on a dividend yield of above 3%, stable dividend
payments, and recent positive performance of the stock. I picked
Microsoft (MSFT), Walgreen (WAG), Johnson & Johnson (JNJ), Eaton Corporation (ETN), and Verizon Communications (VZ).
Microsoft Corporation
Microsoft, the proud maker of
Windows, is soon to unveil its Surface Tablet this month along with
Windows 8. Microsoft is one of the world's largest software companies.
It is the producer of operating systems for various platforms and
devices as well as hardware. The brainchild of Bill Gates and Paul Allen
currently has a huge market capitalization of $261.5 billion and a
94,000-strong workforce. The company's Chief Executive Steve Ballmer
recently put forward the company's future direction as something that will focus more on hardware and online services, in an effort to level up in competition with rival Apple.
Like
fund managers Tepper and Einhorn, Microsoft is likewise favored by Ray
Dalio. Bridgewater has been increasing its position in the company in
the last two quarters. Currently, Microsoft comprises 0.70% of the hedge
fund's total portfolio. It is noted that Bridgewater sold almost all of
its position in the Windows maker during the last quarter of 2011.
Microsoft
is a good dividend payer. Its annualized dividend has been rising
consistently. The positive growth prospect in the future is seen through
the higher EPS estimate for next year of $3.30 compared with the
trailing EPS of $2.00. The net margin of 23.03% suggests that the
company is highly profitable. My FED+ fair value estimate for Microsoft
is about $36 to $44. The stock has at least 25% upside potential to
reach its fair value.
Walgreen
Walgreen's business
involves operating a drugstore chain the U.S. It was incorporated in
1909. The company sells its products and services not only through
drugstores but also various channels. The products
include prescription and nonprescription drugs, household products,
personal care, and beauty care among others. The pharmacy services it
offers include retail, medical facility, infusion, care services, and
mail services. Walgreen is the country's largest drugstore chain with total sales of $72 billion in the fiscal year 2012. Recently, the company announced that it will be a part of preferred pharmacy networks
of four national Medicare plan sponsors (Part D). The plans offered aim
to deliver cost savings for Medicare beneficiaries. The inclusion of
Walgreen as a provider will improve access to pharmacy services.
Bridgewater
has increased its position in the stock six-folds in the second
quarter. During the first quarter, the hedge fund sold over
three-fourths of its holdings. It is remembered that the fund initiated
its position in the company four quarters ago.
WAG has a spotless
record in dividend payment. It continuously pays its investors, and with
a rate that has been increasing through the years. The August payment
amounting to $0.275 is 20% higher than that for August last year at
$0.225. Walgreen is showing robust performance. A higher EPS of $3.72 is
expected next year. The current EPS is $2.42. The long-term annual
growth estimate for the next 5 years is four times (12.77%) that for the
past 5 years (3.57%). Based on this estimate, my FED+ fair value
estimate for the company is about $44 to $64. The stock has at least 24%
upside potential to reach its fair value.
Johnson & Johnson
Johnson
& Johnson is a New Jersey-based healthcare conglomerate that has a
117,900-strong workforce. JNJ produces and sells a wide range of
healthcare products in baby care, oral care, wound care, and women's
health. JNJ's diversified products range from nutritionals and medical
devices to drugs, both over-the-counter drugs and prescription. It is
the maker of prescription drugs Edurant, Xarelto, and Zytiga. JNJ is
also behind brand names like Tylenol, Listerine, Clean & Clear,
Neutrogena, and Band-Aid, among others. JNJ's Janssen Research &
Development, LLC recently presented encouraging data on its phase III trial on canagliflozin,
a type II diabetes treatment candidate, at the European Association for
the Study of Diabetes annual meeting. The diabetes market is one that
JNJ shares with a number of rivals but which has a significant
commercial potential.
The hedge fund has augmented its shares in
JNJ during the second quarter. The company currently makes up 0.33%,
amounting to $22 million, of the fund's total holdings. It has been on
the 13F file of Bridgewater for the last six quarters.
JNJ has a
dividend yield of 3.57%. It has not failed to pay its investors, and the
amount has been rising continuously for many years. For instance, the
August payment of $0.61 is an improvement from that for the same period
last year of $0.57. The growth prospect for JNJ is good. The estimated
EPS for next year is $5.47, higher than the current one, which is $3.24.
My FED+ fair value estimate for the stock is about $54 to $76. The
stock is fairly valued at the moment.
Eaton Corporation
Eaton Corporation is a power management company founded in 1916 that truly has a global reach. With a market capitalization of $15.14 billion,
ETN sells directly or through various channels its products in around
150 countries. It is a provider of electrical components and systems for
a diversified set of industries that include industrial, commercial,
utility, automotive, construction, oil and gas, and agriculture, to name
just a few. TheStreet Ratings
has recently reiterated a buy for Eaton with a rating score of B. The
report mentioned the company strengths in a number of areas including a
solid stock performance, impressive EPS growth, reasonable debt levels,
and good cash flow.
Bridgewater has drastically increased its
holdings in the Cleveland-based firm in the second quarter. From a mere
0.01% share, the company now comprises 0.23% of the fund's portfolio.
Prior to the second quarter, Bridgewater has been selling large chunks
of its shares in ETN.
Eaton's dividend yield based on Finviz.com
data is 3.28%. It has been consistently paying dividends to its
shareholders for years now. The stock is expected to grow to an EPS of
$4.77 next year, slightly higher than the current EPS of $4.18. My FED+
fair value estimate for the stock is about $66 to $90. The stock has at
least 48% upside potential to reach its fair value.
Verizon Communications Inc.
Verizon
Communications was founded in 1983 as Bell Atlantic Corporation. It is a
provider of communications, information, and entertainment products and
services to a wide clientele worldwide. The company has a market
capitalization of $130.42 billion. In 2000, Bell Atlantic changed its
name into Verizon Communications. The New York-based communications
giant is now serving over 94 million retail customers. Recently, Verizon
announced the launching of its 4G LTE service on Oct. 18. It will
become available in 417 markets across the US. The service is said to be
a blazing fast mobile broadband service.
Bridgewater Associates
has decreased its holdings in VZ in the second quarter. It is noted that
last quarter the fund renewed its position in VZ by purchasing $17
million worth of shares. Toward the end of the 2011, the hedge fund sold
its position in the company.
The company has a huge dividend
yield of 4.47%. Verizon is one of the companies that have a great track
record in dividend payments. It does not only pay regular but also
incrementing dividends. The earnings of the company are likewise
expected to grow as shown by a higher EPS next year of $2.83 that is
almost three-folds the EPS of $1.00. My FED+ fair value estimate for the
stock is about $26 to $40. The stock looks a bit expensive at the
current valuation. However, this is mostly due to one-time losses
experienced by Verizon.